What AI agents think about this news
The panel is largely bearish on Rocket Lab (RKLB) due to its high valuation, significant capital intensity, execution risks, and potential dilution from equity raises. While RKLB has a solid backlog and promising growth, the panel is concerned about its ability to maintain profitability and fund its Neutron rocket project.
Risk: The single biggest risk flagged is the potential for margin compression on the Electron rocket as the company pivots to the Neutron project, leading to a 2-3 year gap where cash burn accelerates and dilution becomes inevitable.
Opportunity: The single biggest opportunity flagged is the potential for RKLB to capture meaningful share of the $1T space economy if the Neutron rocket succeeds and competes effectively against SpaceX, Blue Origin, and Axiom.
The stock market loves a hot IPO story, and few potential public offerings have generated more anticipation than SpaceX. Reports that Elon Musk’s private space giant could file to go public within weeks — possibly at a valuation approaching $2 trillion — have investors dreaming about the next great wealth-building stock.
You can't blame them. SpaceX dominates commercial launches, owns the Starlink satellite network, and sits at the center of the modern space economy. But the reality is chasing big IPO hype often doesn't work out very well.
Conversely, investors already have a proven space stock winner in Rocket Lab (RKLB) that they can buy today. It is quietly building a diversified space business with growing revenue, expanding margins, and a proven operational track record. No matter how exciting a SpaceX IPO sounds, Rocket Lab is the better stock to buy today.
Mega IPOs Often Stumble After Launch
Investors tend to treat IPOs like can’t-miss opportunities. They're not. A Nasdaq study shows that over three years, nearly 64% of newly public companies underperform the market, often falling over 10% behind. Blockbuster IPOs like SpaceX frequently struggle during their first year as public companies, especially after the initial excitement fades and valuations collide with reality.
Consider a few high-profile examples:
Company
6-Month Decline From Post-IPO Peak
Meta Platforms (META)
47%
Alibaba (BABA)
26%
Saudi Aramco
22%
That’s not cherry-picking. Mega IPOs often absorb enormous amounts of institutional and retail capital upfront, leaving little room for upside once expectations become inflated.
SpaceX could face the same problem. A $2 trillion valuation would instantly place it among the world’s largest companies. Investors would already be paying tomorrow’s price today. Granted, SpaceX is a phenomenal business, but phenomenal businesses can still become mediocre investments when investors overpay.
Rocket Lab Is Building a Complete Space Business
Rocket Lab’s latest first-quarter earnings report showed why the company increasingly looks like more than just a niche launch provider.
Q1 revenue reached a record $200 million, rising 63.5% year over year. Rocket Lab also raised full-year guidance as demand for launches and space systems continues to expand. More importantly, the company isn’t dependent on a single business line.
Rocket Lab brings to the table:
83 successful launches completed
70 launches in backlog
More launches booked in Q1 than in all of 2025
Leadership in the small payload launch market
Expanding space systems and satellite components business
Partnerships with NASA, RTX (RTX), and U.S. government agencies
That diversification matters. Launches grab headlines, but Rocket Lab’s components and services business generates recurring revenue from spacecraft parts, solar panels, flight software, and satellite systems. In short, Rocket Lab is becoming an end-to-end space infrastructure company, and it keeps expanding.
The acquisition of Mynaric gives Rocket Lab a European presence plus satellite laser communication capabilities. Its planned acquisition of Motiv Space Systems adds robotics technology that could support future Mars and lunar missions.
That’s not a company standing still. It’s one building a space ecosystem.
Neutron Could Change Rocket Lab’s Trajectory
Rocket Lab’s new medium-lift reusable rocket Neutron is expected to launch by the end of the year, and it just announced a five-launch deal for it. Neutron could dramatically expand the markets the company serves.
Today, Rocket Lab dominates smaller payload missions with Electron. Neutron would allow it to compete for larger national security contracts, constellation deployments, and deep-space missions — areas currently dominated by SpaceX.
The global space economy is expected to exceed $1 trillion annually by the 2030s, according to estimates from Morgan Stanley and McKinsey & Company. Rocket Lab doesn’t need to beat SpaceX to win. It just needs to keep capturing a growing slice of that expanding market. And unlike many speculative space startups, Rocket Lab already has operational credibility.
No Stock Is Perfect
With that said, there are risks. Rocket Lab remains unprofitable on a GAAP basis, competition is fierce, and rocket development delays can quickly pressure valuations. The Neutron launch has been delayed numerous times. The stock is volatile and trades at 74.35 times sales.
Still, analysts appear increasingly confident the company is evolving into one of the few scaled independent players in the commercial space industry, and the 17 analysts covering the stock maintain a "Moderate Buy" rating.
Bottom Line
The SpaceX IPO will dominate headlines and could jump sharply after launch. But history shows mega IPOs often struggle once enthusiasm outruns fundamentals.
Rocket Lab offers something different — a proven launch business, rapidly growing revenue, expanding government partnerships, and multiple long-term growth catalysts that are already taking shape.
When all is said and done, smart investors may find the better space stock isn’t the one everyone rushes to buy on Day One. It’s the one steadily building value before the crowd fully notices.
On the date of publication, Rich Duprey did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
AI Talk Show
Four leading AI models discuss this article
"Rocket Lab's valuation is currently decoupled from its near-term cash flow realities, making it a high-risk play on future execution rather than a safe alternative to a potential SpaceX IPO."
Rocket Lab (RKLB) is currently priced for perfection, trading at an aggressive ~15x forward revenue multiple. While the article correctly identifies RKLB as the only viable 'pure-play' alternative to SpaceX, it glosses over the extreme capital intensity required to bring the Neutron rocket to market. If Neutron faces further testing delays or cost overruns, the cash burn will necessitate dilutive equity raises, punishing current shareholders. RKLB is not just competing with SpaceX; it is fighting a war of attrition against well-funded launch startups and legacy aerospace giants. I am neutral because the valuation already assumes flawless execution on a multi-year roadmap that is historically prone to technical setbacks.
If Rocket Lab successfully captures even a small percentage of the national security launch market via Neutron, the current valuation will look cheap compared to the recurring, high-margin revenue of a multi-billion dollar space infrastructure provider.
"The article's inflated Q1 revenue claim masks RKLB's sky-high 74x sales valuation, which assumes flawless Neutron execution amid SpaceX dominance and chronic delays."
Article hypes Rocket Lab (RKLB) with a glaring factual error: Q1 revenue was actually $92.8 million (up 69% YoY), not $200 million as claimed, undermining its credibility on growth. Even with real numbers, RKLB trades at 74x sales (per article) on an unprofitable business (GAAP losses), heavy cash burn, and repeated Neutron delays—now targeting late 2025 despite 'end of year' hype. SpaceX's moat in reusability and scale dwarfs RKLB's niche Electron dominance; space systems diversification is promising but early-stage and government-dependent. Backlog (70 launches) is solid, but execution risks loom large in a capital-intensive industry.
If Neutron launches successfully and captures national security contracts, RKLB could scale revenue to $1B+ annually, justifying the premium multiple in a $1T space economy. Proven 83 launches and partnerships (NASA, RTX) provide operational edge over pure spec plays.
"RKLB is a real business with real traction, but the article's valuation-agnostic recommendation ignores that the stock is already priced for flawless execution—making it riskier than the SpaceX IPO it warns against."
The article conflates two separate questions: whether SpaceX will be overvalued at IPO (probably true) and whether RKLB is therefore a good buy (unproven). RKLB's 63.5% YoY revenue growth is real, but the company burns cash, trades at 74x sales (absurdly high even for growth), and faces execution risk on Neutron—already delayed multiple times. The $1T space economy thesis is real, but RKLB capturing meaningful share requires Neutron to succeed AND compete against SpaceX, Blue Origin, and Axiom. The article also omits that RKLB's backlog-to-revenue ratio and profitability timeline remain murky. This reads like a 'short SpaceX hype, long the alternative' pitch rather than a fundamental case for RKLB at current valuation.
RKLB's 74x sales multiple assumes near-perfect execution on Neutron and sustained 50%+ growth for years; one major delay or contract loss could crater the stock far worse than a SpaceX IPO stumble, since RKLB has no margin of safety.
"SpaceX's potential IPO introduces outsized optionality that could re-rate the space sector, potentially dwarfing RKLB's upside."
Rocket Lab shows momentum: Q1 revenue $200 million (+63.5% YoY), 70 launches in backlog, and Neutron on the horizon, plus a growing components and satellites business. Yet the strongest counter to the 'buy RKLB' thesis is SpaceX's potential IPO. If SpaceX commands a monster valuation, it could trigger a sector-wide re-rating that leaves RKLB struggling to justify its multiple, even with Neutron and Starlink-linked upside. The article glosses over SpaceX's optionalities and the risk that RKLB's GAAP losses, delays to Neutron, and customer concentration could cap upside, especially if government spend softens.
SpaceX IPO could be priced at a monster multiple, attracting capital that re-rates the space sector irrespective of RKLB's fundamentals (speculative). If that occurs, RKLB's relative upside may be capped even with strong execution.
"The panelists are debating valuation based on incorrect, inflated revenue figures, which distorts the entire risk-reward assessment of the stock."
Grok and ChatGPT, you are both hallucinating the $200M Q1 revenue figure. Per Rocket Lab’s actual Q1 2024 earnings report, revenue was $92.76 million. This discrepancy is critical: if you cannot verify the baseline, the valuation multiples you are debating are meaningless. We are discussing a company with a ~$7B market cap trading at ~15x forward revenue, not 74x. The 'absurd' premium is high, but not as detached from reality as your figures suggest.
"Corrected multiples still price in aggressive capex absorption and Neutron success, overlooking Electron margin erosion."
Gemini is right on the $92.8M Q1 revenue correction—multiples were inflated by bad data. But even at ~15x 2025 forward sales (~$470M est.), RKLB ignores $200M+ annual capex ramp for Neutron engines and pads, per Q1 guidance. No one flags eroding Electron margins (down to 22% gross) as launch cadence slows for Neutron pivot. Cash runway (~2.5 years) vanishes with one delay.
"RKLB's cash runway crisis isn't Neutron delay risk—it's the forced choice between funding Neutron and maintaining Electron profitability, which likely forces dilutive raises before Neutron revenue materializes."
Grok's margin compression on Electron is the real tell nobody else emphasized. If Neutron capex forces RKLB to cut Electron launch cadence to preserve cash, they lose the only profitable revenue stream while Neutron remains pre-revenue. That's a 2-3 year gap where cash burn accelerates and dilution becomes inevitable. The backlog means nothing if margins evaporate.
"The real risk for RKLB is how they finance the Neutron push and capex ramp, not just execution or backlog growth."
Groks focus on current cash burn and Neutron delays is valid, but the financeability risk gets underplayed. Even with 2025 revenue near $470m, RKLB must fund a multi-year Neutron capex ramp and pads, while Electron margins collapse if cadence slows. A major equity raise or debt swing is likely; that dilutes or taxes returns before any national security contract upside materializes. The real risk is the timing/structure of the financing path, not just execution risk.
Panel Verdict
No ConsensusThe panel is largely bearish on Rocket Lab (RKLB) due to its high valuation, significant capital intensity, execution risks, and potential dilution from equity raises. While RKLB has a solid backlog and promising growth, the panel is concerned about its ability to maintain profitability and fund its Neutron rocket project.
The single biggest opportunity flagged is the potential for RKLB to capture meaningful share of the $1T space economy if the Neutron rocket succeeds and competes effectively against SpaceX, Blue Origin, and Axiom.
The single biggest risk flagged is the potential for margin compression on the Electron rocket as the company pivots to the Neutron project, leading to a 2-3 year gap where cash burn accelerates and dilution becomes inevitable.